This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer. A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.
1 Primary · 7 Secondary · Reporting Duration: From C1D1 to death from any cause, average of 9 months
Experimental Treatment
84 Total Participants · 1 Treatment Group
Primary Treatment: CTX-009 Treatment · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: